HUTCHMED (NASDAQ:HCM) Sets New 1-Year Low – Here’s What Happened

HUTCHMED (China) Limited (NASDAQ:HCM) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $12.89 and last traded at $12.87, with a volume of 4366 shares traded. The stock had previously closed at $13.20.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Stock Up 1.0 %

The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average is $14.54 and its 200-day moving average is $17.07.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC raised its holdings in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after buying an additional 49,366 shares during the last quarter. State Street Corp raised its stake in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after acquiring an additional 3,078 shares during the last quarter. XY Capital Ltd bought a new position in shares of HUTCHMED in the fourth quarter worth about $673,000. Crossmark Global Holdings Inc. lifted its position in shares of HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after purchasing an additional 1,799 shares in the last quarter. Finally, M&G PLC grew its stake in shares of HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.